References

1. 1. Sigalos J.T., Pastuszak A.W. The safety and efficacy of growth hormone secretagogues // Sex. Med. Rev. 2018. V. 6. № 1. P. 45. https://doi.org/10.1016/j.sxmr.2017.02.004
2. 2. Patchett A.A., Nargund R.P., Tata J.R., Chen M.H., Barakat K.J., Johnston D.B., Cheng K., Chan W.W., Butler B., Hickey G. Design and biological activities of L-163,191 (MK-0677): A potent, orally active growth hormone secretagogue // Proc. Natl. Acad. Sci. USA. 1995. V. 92. № 15. P. 7001. https://doi.org/10.1073/pnas.92.15.7001
3. 3. Ishida J., Saitoh M., Ebner N., Springer J., Anker S.D., von Haehling S. Growth hormone secretagogues: History, mechanism of action, and clinical development // JCSM Rapid Commun. 2020. V. 3. № 1. P. 25. https://doi.org/10.1002/rco2.9
4. 4. Copinschi G., Van Onderbergen A., L’Hermite-Balériaux M., Mendel C.M., Caufriez A., Leproult R., Bolognese J.A., De Smet M., Thorner M.O., Van Cauter E. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men // J. Clin. Endocrinol Metab. 1996. V. 81. № 8. P. 2776. https://doi.org/10.1210/jcem.81.8.8768828
5. 5. Svensson J., Lönn L., Jansson J.O., Murphy G., Wyss D., Krupa D., Cerchio K., Polvino W., Gertz B., Boseaus I., Sjöström L., Bengtsson B.A. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure // J. Clin. Endocrinol. Metab. 1998. V. 83. № 2. P. 362. https://doi.org/10.1210/jcem.83.2.4539
6. 6. Murphy M.G., Bach M.A., Plotkin D., Bolognese J., Ng J., Krupa D., Cerchio K., Gertz B.J. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults // J. Bone Miner. Res. 1999. V. 14. № 7. P. 1182. https://doi.org/10.1359/jbmr.1999.14.7.1182
7. 7. Nass R., Pezzoli S.S., Oliveri M.C., Patrie J.T., Harrell Jr F.E., Clasey J.L., Heymsfield S.B., Bach M.A., Vance M.L., Thorner M.O. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: A randomized trial (trials) // Ann. Int. Med. 2008. V. 149. № 9. P. 601. https://doi.org/10.7326/0003-4819-149-9-200811040-00003
8. 8. Adunsky A., Chandler J., Heyden N., Lutkiewicz J., Scott B.B., Berd Y., Liu N., Papanicolaou D.A. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: A multicenter, randomized, placebo-controlled phase IIb study // Arch. Gerontol. Geriatr. 2011. V. 53. № 2. P. 183. https://doi.org/10.1016/j.archger.2010.10.004
9. 9. World Anti-Doping Agency. World Anti-Doping Code. The 2021 Prohibited List. https://www.wada-ama.org/sites/default/files/resources/files/2021list_en.pdf (2021) (31.01.2023).
10. 10. Baumann G.P. Growth hormone doping in sports: A critical review of use and detection strategies // Endocr. Rev. 2012.V. 33. № 2. P. 155. https://doi.org/10.1210/er.2011-1035
11. 11. Constanzer M.L., Chavez-Eng C.M., Matuszewski B.K. Determination of a novel growth hormone secretagogue (MK-677) in human plasma at picogram levels by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry // J. Chromatogr. B: Biomed. Sci. Appl. 1997. V. 693. № 1. P. 131. https://doi.org/10.1016/s0378-4347 (97)00035-2
12. 12. Дмитриева Е.В., Темердашев А.З., Азарян А.А., Гашимова Э.М. Определение андарина (S-4), селективного модулятора андрогенных рецепторов, и ибутаморена (МК-677), непептидного секретагога гормона роста, в моче ультравысокоэффективной жидкостной хроматографией с тандемным масс- спектрометрическим детектированием // Журн. аналит. химии. 2018. Т. 73. № 7. С. 523. (Dmitrieva E.V., Temerdashev A.Z., Azaryan A.A., Gashimova E.M. Determination of andarine (S-4), a selective androgen receptor modulator, and ibutamoren (MK-677), a nonpeptide growth hormone secretagogue, in urine by ultra-high performance liquid chromatography with tandem mass-spectrometric detection // J. Anal. Chem. 2018. V. 73. № 7. P. 674. https://doi.org/10.1134/S1061934818070031)
13. 13. Дмитриева Е.В., Темердашев А.З., Азарян А.А., Гашимова Э.М. Использование твердофазной экстракции для определения используемых в спорте лекарственных средств в моче человека методом УВЭЖХ–МС/МС // Аналитика и контроль. 2018. Т. 22. № 3. С. 236. https://doi.org/10.15826/analitika.2018.22.3.008
14. 14. Cuervo D., Loli C., Fernández-Álvarez M., Muñoz G., Carreras D. Determination of doping peptides via solid-phase microelution and accurate mass quadrupole time-of-flight LC–MS // J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2017. V. 1065–1066. P. 134. https://doi.org/10.1016/j.jchromb.2017.08.044
15. 15. Sobolevsky T., Krotov G., Dikunets M., Nikitina M., Mochalova E., Rodchenkov G. Anti-doping analyses at the Sochi Olympic and Paralympic Games 2014 // Drug Test. Anal. 2014. V. 6. № 11–12. P. 1087. https://doi.org/10.1002/dta.1734
16. 16. Cutler C., Viljanto M., Taylor P., Habershon-Butcher J., Van Eenoo P. Equine metabolism of the growth hormone secretagogue MK-0677 in vitro and in urine and plasma following oral administration // Drug Test. Anal. 2022. V. 14. № 7. P. 1273. https://doi.org/10.1002/dta.3252
17. 17. Темердашев А.З., Дмитриева Е.В. Методы определения селективных модуляторов андрогенных рецепторов // Журн. аналит. химии. 2020. Т. 75. № 7. С. 579. (Temerdashev A.Z., Dmitrieva E.V. Methods for the determination of selective androgen receptor modulators // J. Anal. Chem. 2020. V. 75. № 7. P. 835. https://doi.org/10.1134/S1061934820070187)
18. 18. Viette V., Fathi M., Rudaz S., Hochstrasser D., Veuthey J.-L. Current role of liquid chromatography coupled to mass spectrometry in clinical toxicology screening methods // Clin. Chem. Lab. Med. 2011. V. 49. № 7. P. 1091. https://doi.org/10.1515/CCLM.2011.182
19. 19. Chapman I.M., Bach M.A., Van Cauter E., Farmer M., Krupa D., Taylor A.M., Schilling L.M., Cole K.Y., Skiles E.H., Pezzoli S.S., Hartman M.L., Veldhuis J.D., Gormley G.J., Thorner M.O. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects // J. Clin. Endocrinol. Metab. 1996. V. 81. № 12. P. 4249. https://doi.org/10.1210/jcem.81.12.8954023
20. 20. Sobolevsky T., Prasolov I., Rodchenkov G. Urinary metabolism of ibutamoren, a small molecule growth hormone secretagogue / Recent advances in doping analysis (21): Proceedings of the Manfred-Donike-Workshop; 31th Cologne Workshop on Dope Analysis. Köln: Sportverl. Strauß (Verlag), 2013. P. 182.